Symbols / NERV $5.23 -0.95% Minerva Neurosciences, Inc.
NERV Chart
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 226.33M |
| Enterprise Value | 211.15M | Income | -293.42M | Sales | — |
| Book/sh | -3.25 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -10.90 | PEG | — |
| P/S | — | P/B | -1.61 | P/C | — |
| EV/EBITDA | -13.99 | EV/Sales | — | Quick Ratio | 35.93 |
| Current Ratio | 36.28 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -34.67 | EPS next Y | -0.48 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-11 07:00 | ROA | -13.97% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 43.27M |
| Shs Float | 24.62M | Short Float | 1.38% | Short Ratio | 2.97 |
| Short Interest | — | 52W High | 12.46 | 52W Low | 1.15 |
| Beta | -0.21 | Avg Volume | 218.95K | Volume | 225.80K |
| Target Price | $7.25 | Recom | Hold | Prev Close | $5.28 |
| Price | $5.23 | Change | -0.95% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$5.23
Latest analyst target
3. DCF / Fair value
$-3.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.23
Low
$7.00
High
$7.50
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2025-11-06 | main | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2025-02-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-06 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-07 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-05-02 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-08-02 | main | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-05-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $8 |
| 2023-05-02 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2023-03-09 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2022-11-10 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-10-17 | down | JMP Securities | Market Outperform → Market Perform | — |
- Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - Stock Titan Mon, 06 Apr 2026 21
- Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - tipranks.com Mon, 06 Apr 2026 21
- Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail Fri, 03 Apr 2026 22
- After 16 years, Minerva’s president leaves as new business chief joins - Stock Titan hu, 02 Apr 2026 20
- Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha ue, 31 Mar 2026 15
- Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative ue, 21 Oct 2025 07
- Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st Mon, 16 Feb 2026 08
- [Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan Wed, 01 Apr 2026 20
- Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - Stock Titan hu, 02 Apr 2026 20
- No approved drug exists for these schizophrenia symptoms; Minerva starts Phase 3 - Stock Titan ue, 31 Mar 2026 20
- NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - Stock Titan ue, 31 Mar 2026 20
- Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - Stock Titan ue, 31 Mar 2026 21
- Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - Stock Titan ue, 31 Mar 2026 20
- Schizophrenia drug combo showed no safety issues as Phase 3 starts - Stock Titan Wed, 25 Mar 2026 07
- Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan Wed, 11 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
15.10
-30.87%
|
21.85
-5.50%
|
23.12
-8.37%
|
25.23
|
| Research And Development |
|
5.76
-51.60%
|
11.90
-6.35%
|
12.71
-13.27%
|
14.65
|
| Selling General And Administration |
|
9.34
-6.09%
|
9.95
-4.46%
|
10.41
-1.59%
|
10.58
|
| General And Administrative Expense |
|
9.34
-6.09%
|
9.95
-4.46%
|
10.41
-1.59%
|
10.58
|
| Other Gand A |
|
9.34
-6.09%
|
9.95
-4.46%
|
10.41
-1.59%
|
10.58
|
| Total Expenses |
|
15.10
-30.87%
|
21.85
-5.50%
|
23.12
-8.37%
|
25.23
|
| Operating Income |
|
-15.10
+30.87%
|
-21.85
+5.50%
|
-23.12
+8.37%
|
-25.23
|
| Total Operating Income As Reported |
|
-15.10
+30.87%
|
-21.85
+5.50%
|
-23.12
+8.37%
|
-25.23
|
| EBITDA |
|
-293.42
-4971.17%
|
6.02
+127.77%
|
-21.69
+12.16%
|
-24.69
|
| Normalized EBITDA |
|
-294.31
-6291.91%
|
4.75
+120.59%
|
-23.09
+8.46%
|
-25.22
|
| Reconciled Depreciation |
|
0.01
-75.78%
|
0.02
-27.48%
|
0.03
+263.94%
|
0.01
|
| EBIT |
|
-293.42
-4989.50%
|
6.00
+127.63%
|
-21.72
+12.06%
|
-24.70
|
| Total Unusual Items |
|
0.89
-29.82%
|
1.27
-9.07%
|
1.40
+164.01%
|
0.53
|
| Total Unusual Items Excluding Goodwill |
|
0.89
-29.82%
|
1.27
-9.07%
|
1.40
+164.01%
|
0.53
|
| Net Income |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Pretax Income |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Net Non Operating Interest Income Expense |
|
-3.10
+31.99%
|
-4.56
+44.92%
|
-8.28
-11.83%
|
-7.41
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
4.56
-44.92%
|
8.28
+11.83%
|
7.41
|
| Net Interest Income |
|
-3.10
+31.99%
|
-4.56
+44.92%
|
-8.28
-11.83%
|
-7.41
|
| Interest Expense |
|
0.00
-100.00%
|
4.56
-44.92%
|
8.28
+11.83%
|
7.41
|
| Interest Income Non Operating |
|
—
|
—
|
1.44
+158.09%
|
0.56
|
| Interest Income |
|
—
|
—
|
1.44
+158.09%
|
0.56
|
| Other Income Expense |
|
-275.22
-1088.23%
|
27.85
+1893.28%
|
1.40
+164.01%
|
0.53
|
| Other Non Operating Income Expenses |
|
-276.11
-1138.82%
|
26.58
|
—
|
—
|
| Gain On Sale Of Security |
|
0.89
-29.82%
|
1.27
-9.07%
|
1.40
+164.01%
|
0.53
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Net Income From Continuing Operation Net Minority Interest |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Net Income From Continuing And Discontinued Operation |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Net Income Continuous Operations |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Normalized Income |
|
-294.31
-174832.83%
|
0.17
+100.54%
|
-31.40
+3.79%
|
-32.64
|
| Net Income Common Stockholders |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Diluted EPS |
|
-34.67
-18347.37%
|
0.19
+104.12%
|
-4.61
+23.29%
|
-6.01
|
| Basic EPS |
|
-34.67
-18347.37%
|
0.19
+104.12%
|
-4.61
+23.29%
|
-6.01
|
| Basic Average Shares |
|
8.46
+11.82%
|
7.57
+16.33%
|
6.51
+21.84%
|
5.34
|
| Diluted Average Shares |
|
8.46
+11.75%
|
7.57
+16.41%
|
6.51
+21.84%
|
5.34
|
| Diluted NI Availto Com Stockholders |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Total Other Finance Cost |
|
3.10
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
97.97
+163.76%
|
37.14
-34.72%
|
56.90
+3.29%
|
55.09
|
| Current Assets |
|
83.10
+273.16%
|
22.27
-46.98%
|
42.00
+4.59%
|
40.16
|
| Cash Cash Equivalents And Short Term Investments |
|
82.30
+285.27%
|
21.36
-47.79%
|
40.91
+13.35%
|
36.09
|
| Cash And Cash Equivalents |
|
82.30
+285.27%
|
21.36
-47.79%
|
40.91
+13.35%
|
36.09
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Current Assets |
|
0.70
-13.54%
|
0.81
-18.48%
|
0.99
-75.04%
|
3.97
|
| Total Non Current Assets |
|
14.87
-0.04%
|
14.87
-0.15%
|
14.90
-0.21%
|
14.93
|
| Net PPE |
|
0.00
-100.00%
|
0.01
-50.00%
|
0.01
-33.33%
|
0.02
|
| Gross PPE |
|
—
|
—
|
—
|
0.02
|
| Properties |
|
—
|
—
|
—
|
—
|
| Buildings And Improvements |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
—
|
—
|
—
|
0.02
|
| Goodwill And Other Intangible Assets |
|
14.87
+0.00%
|
14.87
-0.11%
|
14.89
-0.17%
|
14.91
|
| Goodwill |
|
14.87
+0.00%
|
14.87
+0.00%
|
14.87
+0.00%
|
14.87
|
| Other Intangible Assets |
|
—
|
—
|
0.02
-60.00%
|
0.04
|
| Total Liabilities Net Minority Interest |
|
238.72
+279.90%
|
62.84
-26.38%
|
85.36
+13.64%
|
75.11
|
| Current Liabilities |
|
2.29
-19.26%
|
2.84
-15.08%
|
3.34
+142.49%
|
1.38
|
| Payables And Accrued Expenses |
|
2.29
-7.41%
|
2.47
-10.04%
|
2.75
+101.77%
|
1.36
|
| Payables |
|
0.64
-60.21%
|
1.61
-10.94%
|
1.81
+86.18%
|
0.97
|
| Accounts Payable |
|
0.64
-60.21%
|
1.61
-10.94%
|
1.81
+86.18%
|
0.97
|
| Current Accrued Expenses |
|
1.65
+90.66%
|
0.87
-8.31%
|
0.94
+140.24%
|
0.39
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.00
-100.00%
|
0.36
-38.52%
|
0.59
+3883.07%
|
0.01
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
236.43
+294.04%
|
60.00
-26.84%
|
82.02
+11.23%
|
73.73
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
60.00
+0.00%
|
60.00
-26.84%
|
82.02
+11.23%
|
73.73
|
| Preferred Securities Outside Stock Equity |
|
4.96
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
-140.75
-447.80%
|
-25.69
+9.71%
|
-28.46
-42.12%
|
-20.02
|
| Common Stock Equity |
|
-140.75
-447.80%
|
-25.69
+9.71%
|
-28.46
-42.12%
|
-20.02
|
| Capital Stock |
|
0.00
+519.03%
|
0.00
+0.00%
|
0.00
+30.90%
|
0.00
|
| Common Stock |
|
0.00
+519.03%
|
0.00
+0.00%
|
0.00
+30.90%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
43.27
+518.79%
|
6.99
+0.00%
|
6.99
+30.96%
|
5.34
|
| Ordinary Shares Number |
|
43.27
+518.79%
|
6.99
+0.00%
|
6.99
+30.96%
|
5.34
|
| Additional Paid In Capital |
|
548.05
+48.25%
|
369.68
+0.36%
|
368.36
+6.22%
|
346.79
|
| Retained Earnings |
|
-688.80
-74.21%
|
-395.38
+0.36%
|
-396.82
-8.18%
|
-366.81
|
| Total Equity Gross Minority Interest |
|
-140.75
-447.80%
|
-25.69
+9.71%
|
-28.46
-42.12%
|
-20.02
|
| Total Capitalization |
|
-140.75
-447.80%
|
-25.69
+9.71%
|
-28.46
-42.12%
|
-20.02
|
| Working Capital |
|
80.81
+315.85%
|
19.43
-49.74%
|
38.66
-0.31%
|
38.78
|
| Invested Capital |
|
-140.75
-447.80%
|
-25.69
+9.71%
|
-28.46
-42.12%
|
-20.02
|
| Total Debt |
|
—
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
—
|
| Net Tangible Assets |
|
-155.62
-283.65%
|
-40.56
+6.42%
|
-43.34
-24.07%
|
-34.94
|
| Tangible Book Value |
|
-155.62
-283.65%
|
-40.56
+6.42%
|
-43.34
-24.07%
|
-34.94
|
| Derivative Product Liabilities |
|
171.46
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.51
+30.89%
|
-19.55
-32.23%
|
-14.78
+40.01%
|
-24.65
|
| Cash Flow From Continuing Operating Activities |
|
-13.51
+30.89%
|
-19.55
-32.23%
|
-14.78
+40.01%
|
-24.65
|
| Net Income From Continuing Operations |
|
-293.42
-20492.68%
|
1.44
+104.80%
|
-30.01
+6.55%
|
-32.11
|
| Depreciation Amortization Depletion |
|
0.01
-75.78%
|
0.02
-27.48%
|
0.03
+263.94%
|
0.01
|
| Depreciation |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
0.00
|
| Amortization Cash Flow |
|
0.00
-100.00%
|
0.02
-33.33%
|
0.03
+200.01%
|
0.01
|
| Depreciation And Amortization |
|
0.01
-75.78%
|
0.02
-27.48%
|
0.03
+263.94%
|
0.01
|
| Amortization Of Intangibles |
|
0.00
-100.00%
|
0.02
-33.33%
|
0.03
+200.01%
|
0.01
|
| Other Non Cash Items |
|
—
|
-22.02
-365.81%
|
8.28
+11.83%
|
7.41
|
| Stock Based Compensation |
|
1.33
+0.14%
|
1.33
-32.66%
|
1.97
-52.09%
|
4.11
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Deferred Tax |
|
—
|
—
|
—
|
—
|
| Deferred Income Tax |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
279.21
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
279.21
|
—
|
—
|
—
|
| Change In Working Capital |
|
-0.63
-97.24%
|
-0.32
-106.49%
|
4.94
+221.62%
|
-4.06
|
| Change In Prepaid Assets |
|
0.11
-40.31%
|
0.18
+229.08%
|
-0.14
-128.45%
|
0.50
|
| Change In Payables And Accrued Expense |
|
-0.74
-47.26%
|
-0.50
-125.66%
|
1.96
+236.18%
|
-1.44
|
| Change In Accrued Expense |
|
0.32
+203.71%
|
-0.31
-127.16%
|
1.13
+302.07%
|
-0.56
|
| Change In Payable |
|
-1.06
-436.27%
|
-0.20
-123.63%
|
0.84
+194.58%
|
-0.88
|
| Change In Account Payable |
|
-1.06
-436.27%
|
-0.20
-123.63%
|
0.84
+194.58%
|
-0.88
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-3.12
|
| Change In Other Current Assets |
|
—
|
0.00
-100.00%
|
3.12
+200.00%
|
-3.12
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Investing Cash Flow |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Net PPE Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Purchase Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.02
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.02
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
74.45
|
0.00
-100.00%
|
19.60
+392074120.00%
|
-0.00
|
| Cash Flow From Continuing Financing Activities |
|
74.45
|
0.00
-100.00%
|
19.60
+392074120.00%
|
-0.00
|
| Net Common Stock Issuance |
|
—
|
0.00
-100.00%
|
20.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
—
|
| Net Other Financing Charges |
|
-5.55
|
—
|
-0.40
-7925760.00%
|
-0.00
|
| Changes In Cash |
|
60.94
+411.70%
|
-19.55
-505.70%
|
4.82
+119.54%
|
-24.66
|
| Beginning Cash Position |
|
21.46
-47.67%
|
41.01
+13.31%
|
36.19
-40.52%
|
60.86
|
| End Cash Position |
|
82.40
+283.94%
|
21.46
-47.67%
|
41.01
+13.31%
|
36.19
|
| Free Cash Flow |
|
-13.51
+30.89%
|
-19.55
-32.23%
|
-14.78
+40.05%
|
-24.66
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Amortization Of Securities |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
—
|
0.00
-100.00%
|
20.00
|
0.00
|
| Issuance Of Capital Stock |
|
80.00
|
0.00
-100.00%
|
20.00
|
0.00
|
| Net Preferred Stock Issuance |
|
80.00
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
80.00
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 42026-04-01 View
- 10-K2026-03-11 View
- 8-K2026-03-11 View
- 8-K2026-02-03 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 42025-12-23 View
- 8-K2025-12-22 View
- 8-K2025-11-19 View
- 42025-11-18 View
- 10-Q2025-11-05 View
- 8-K2025-10-22 View
- 10-Q2025-08-14 View
- 10-Q2025-05-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|